Cystatin C is an essential secretory cofactor for neurogenesis with potent protease inhibitor activities. Polymorphisms of cystatin C are genetically associated with Alzheimer's disease (AD), and the L68Q mutation causes hereditary cerebral hemorrhage with amyloidosis of the Icelandic type, in which cystatin C and ␤-amyloid are colocalized in cortical blood vessels. To determine whether cystatin C and ␤-amyloid also colocalize in brain amyloid plaques, we analyzed transgenic mice expressing the Swedish APP (SweAPP) mutation. We found high levels of cystatin C in astrocytes surrounding ␤-amyloid plaques, and discrete layers of cystatin C attached to amyloid plaque cores covered by a layer of ␤-amyloid. In addition, cystatin C accumulated in reactive astrocytes throughout the brain, independently of, and before the onset of, amyloid plaque formation. These results show that expression of SweAPP is associated with increased cystatin C in reactive astrocytes, and they suggest an early role of cystatin C in appositional amyloid plaque growth.
INTRODUCTION
Cystatin C is an ubiquitously expressed endogenous inhibitor of cystein proteinases, including the cathepsins B, H, L, and S (Abrahamson, 1994; Barrett et al., 1984) . In brain, cystatin C is an autocrine/paracrine cofactor of FGF-2 for the proliferation of neural stem cells, and thus plays a central role in supporting neurogenesis in vivo (Taupin et al., 2000) . In adult brains, cystatin C is synthesized by astrocytes and neuronal progenitor cells (Lignelid et al., 1997; Taupin et al., 2000; Yasuhara et al., 1993) ; it is a secretory protein that can also reach endocytic cellular compartments (Pierre & Mellman, 1998) . Brain levels of cystatin C increase in response to injury including ischemia and axotomy (Ishimaru et al., 1996; Katakai et al., 1997; Miyake et al., 1996; Palm et al., 1995) .
During migration through the secretory pathway, the biological activity of cystatin C is inhibited by dimerization. This biophysical property to form homodimers makes cystatin C an amyloidogenic protein: Dimerization is accelerated by the pathogenic L68Q mutation that causes hereditary cerebral hemorrhage with amyloidosis-Icelandic type (HCHWA-I), an autosomal dominant disorder characterized by repeated cerebral hemorrhages caused by massive amyloidosis of the brain vasculature (Ghiso et al., 1986; Gudmundsson et al., 1972; Levy et al., 1989; Palsdottir et al., 1988) . The mutant protein lacks the first 10 amino terminal residues, it aggregates more readily than the wild type protein, and it is deposited predominantly in small blood vessels throughout the brain (Gudmundsson et al., 1972; Palsdottir et al., 1988) . Immunohistochemical analyses of brain tissue obtained from
